Skip to content
    IDXX
    Earnings call· Mar 2025(Q1 FY25)

    IDEXX LABORATORIES INC /DE Q1 FY25 earnings call IDXX

    May 1, 2025 Source

    Executive summary

    IDEXX Laboratories Q1 FY25 — Solid Start with Innovation Traction Amidst Macro Headwinds

    IDEXX Laboratories delivered a solid first quarter, with organic revenue growth driven by strong execution and the successful commercialization of new diagnostic platforms like IDEXX Cancer Dx and inVue Dx. Despite ongoing macroeconomic pressures leading to a decline in U.S. clinical visits, the company maintained its full-year organic revenue and comparable operating margin guidance, demonstrating confidence in its innovation-led growth strategy and resilient pet healthcare market. Management highlighted the importance of new product ramps and continued focus on customer value to navigate dynamic market conditions.

    Highlights

    5

    • Overall revenues increased 5% organically, driven by strong execution and innovation.

    • CAG Diagnostics recurring revenues grew 4.5% organically, net of a 1.5% equivalent days headwind.

    • Global premium instrument installed base expanded 9% year-over-year.

    • EPS grew 7% on a comparable basis to $2.96 per share, supported by gross margin gains.

    • IDEXX Cancer Dx and IDEXX inVue Dx launches gaining commercial traction, with over 1,000 practices ordering Cancer Dx and 900 inVue Dx placements by end of April.

    Concerns

    5

    • Global same-store growth headwinds, including a 2.6% decline in U.S. clinical visits.

    • CAG instrument revenues decreased 5% organically against high prior-year placement levels.

    • Global Rapid Assay revenues declined 2% organically, impacted by customer shift to Catalyst platform (5% headwind).

    • Foreign exchange reduced operating profit by $4 million and EPS by approximately $0.04 per share in Q1.

    • Full-year net income to free cash flow conversion outlook revised down to 80%-85% due to litigation and tariff planning.

    Guidance & targets

    17
    CategoryTargetConfidence
    Full-year Reported Revenues
    $4.095B to $4.210B
    high materiality
    High
    Full-year Organic Revenue Growth
    6% to 9%
    high materiality
    High
    Full-year CAG Diagnostics Recurring Revenue Growth
    5% to 8%
    medium materiality
    High
    Full-year Global Net Price Realization (CAG Diagnostics)
    4% to 4.5% at midpoint
    medium materiality
    High
    Full-year IDEXX inVue Dx Placements
    4,500
    medium materiality
    High
    Full-year Reported Operating Margins
    31.1% to 31.6%
    high materiality
    High
    Full-year Comparable Operating Margin Expansion
    30 to 80 basis points
    high materiality
    High
    Full-year EPS Outlook
    $11.93 to $12.43 per share
    high materiality
    High
    Full-year Comparable EPS Growth
    8% to 12%
    high materiality
    High
    Q2 Reported Revenue Growth
    5% to 7.5%
    medium materiality
    High
    Q2 Organic Revenue Growth
    6% to 8.5%
    medium materiality
    High
    Q2 Organic CAG Diagnostics Revenue Growth
    5% to 7.5%
    medium materiality
    High
    Q2 Reported Operating Margins
    32.9% to 33.4%
    medium materiality
    High
    Full-year Net Income to Free Cash Flow Conversion
    80% to 85%
    medium materiality
    Medium
    Full-year Gross Leverage Ratios
    similar levels to Q1
    low materiality
    High
    IDEXX inVue Dx FNA expansion
    later in 2025
    medium materiality
    High
    Oncology menu expansion
    broaden to address majority of canine cancer cases
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    CAG Diagnostics
    CAG Diagnostics recurring revenue growth was solid despite equivalent days and U.S. clinical visit headwinds, driven by international strength and execution. Modality gains were supported by strong consumable revenues and premium instrument installed base expansion. Rapid Assay was impacted by internal platform shifts.
    Organic growth net of 1.5% equivalent days headwindInternational organic growth: 8.5% (double-digit days adjusted)U.S. organic growth: 3% (net of days headwind)Global net price improvement: 4%Days adjusted volume gains: ~2%U.S. clinical visits decline: 2.6%VetLab consumable revenues organic growth: 10%Global premium instrument installed base growth: 9%CAG premium instruments placed: 4,163 (down 13% YoY)U.S. premium instruments placed: 1,544 (up 12% YoY)Competitive and greenfield Catalyst placements: 7% growth in U.S., 5% in EuropeGlobal EVI metric growth: double-digitIDEXX inVue Dx analyzers placed (North America): 302Global Rapid Assay revenues organic decline: 2%Rapid Assay headwind from shift to Catalyst: 5%Global lab revenues organic growth: 1%U.S. lab revenues growth: low single-digitInternational lab revenues growth: solid
    		—4.5% organic——
    Water
    Water segment achieved strong organic growth, with Europe being a key driver.
    European region revenue expansion: double-digit
    		—7% organic——
    Livestock, Poultry and Dairy (LPD)
    LPD segment delivered solid organic gains, building on momentum from the second half of 2024.
    		—4% organic——
    Veterinary Software and Diagnostic Imaging
    Strong organic growth driven by recurring revenues and momentum in cloud-based software placements, including benefits from a prior-year acquisition.
    Reported growth: 9%Recurring revenue growth: 9% organicCloud-based software placements momentum
    		—7% organic——

    Operational metrics

    19
    Gross profit growth
    5%YoY reported
    Q1 FY25

    Supported by solid gross margin gains.

    Gross margin
    62.4%up 80 bps comparable
    Q1 FY25

    Reflected benefits from business mix and instrument mix.

    Operating expenses growth
    4%YoY reported
    Q1 FY25

    Net of a favorable adjustment to litigation expense accrual and FX impacts, driven by R&D and commercial spending.

    EPS growth
    5%YoY reported
    Q1 FY25

    Net of a 3% EPS growth benefit from litigation expense accrual adjustment.

    Operating profit FX impact
    $4Mreduction
    Q1 FY25

    Reduced operating profit, net of a $4 million hedge gain.

    EPS FX impact
    $0.04reduction
    Q1 FY25

    Reduced EPS, net of a $4 million hedge gain.

    Net income to free cash flow conversion ratio
    95%
    TTM

    On a trailing 12-month basis.

    Gross leverage ratio
    0.7x
    Q1 FY25

    At quarter end.

    Net leverage ratio
    0.6x
    Q1 FY25

    Net of cash, at quarter end.

    Diluted shares outstanding reduction
    2.4%
    last year

    Supported by share repurchases.

    Capital allocated to share repurchases
    $415M
    Q1 FY25

    During the first quarter.

    Full-year EPS FX impact
    -$0.10negative impact
    FY25

    Estimated full year EPS impact from foreign exchange.

    Full-year EPS benefit from litigation accrual
    $0.08benefit
    FY25

    Benefit from favorable adjustment to discrete litigation expense accrual.

    Pet population CAGR
    3%vs. 1% historical annual growth
    2019-2024

    Represents a higher baseline of absolute number of pets, supporting strong tailwinds.

    ezyVet and Neo placement growth
    double-digit
    Q1 FY25

    Placement growth in leading cloud-native PIMS, particularly in multi-location practices and corporate accounts.

    Vello user growth
    20%from Q4
    Q1 FY25

    Growth in users for the cloud-native client engagement platform.

    China revenue contribution
    <1%
    Q1 FY25

    Less than 1% of company revenues come from China, impacting tariff exposure.

    FX sensitivity (revenue)
    $11M
    FY25

    Sensitivity of top line to 1% change in foreign exchange rates.

    FX sensitivity (operating profit)
    $4M
    FY25

    Sensitivity of operating profit to 1% change in foreign exchange rates.

    Industry KPIs

    12
    MetricValueDetails
    Tariff impactestimated impacts
    System utilizationwell aligned with expectations
    Pricing realized price4%%
    New product launch ramp302instruments
    Procedure volume growth-2.6%%
    FCF conversion leverage guidance80% to 85%%
    Installed base system placements9%%
    Segment franchise organic growth4.5%%
    Consumables recurring revenue mix10%%
    Sales force commercial capacity buildcompleted onboarding and training
    Indicated addressable patient population3%%
    Pivotal trial clinical evidence milestoneslaunched

    Product announcements

    2
    ProductTypeDetails
    IDEXX Cancer Dxlaunch
    IDEXX inVue Dxlaunch

    Risks & headwinds

    5
    Global same-store growth headwindsQ1 FY25, ongoing

    U.S. clinical visits declined 2.6% overall in Q1

    Mitigation: Increased diagnostic frequency and utilization per clinical visit; strong execution, new business gains, customer retention, net price realization; innovation launches (Cancer Dx, inVue Dx).

    Macroeconomic conditions and economic uncertaintyOngoing

    Pressuring clinical visits, particularly wellness visits

    Mitigation: Focus on innovation, customer engagement, and operational efficiency; pet healthcare market resiliency (stable pet population, longer pet lifespans, aging pet population).

    Dynamic tariff environmentFY25

    Incorporated estimates for China's retaliatory tariffs; 1% full-year reported revenue growth improvement related to FX; full-year net income to FCF conversion revised to 80-85% due to tariff planning.

    Mitigation: Relatively well-positioned (65% U.S. revenues, <1% China revenues); focus on continuous supply to customers; minimizing impacts through operational planning and balance sheet leverage; resilient supply chains.

    Foreign exchange impactQ1 FY25, FY25

    Reduced Q1 operating profit by $4M and EPS by ~$0.04/share; estimated negative $0.10/share full-year EPS impact.

    Mitigation: Hedging strategies (Q1 hedge gain of $4M); transparent reporting of sensitivities (1% FX change = $11M revenue, $4M operating profit impact).

    Customer shift from Rapid Assay to Catalyst platformQ1 FY25

    5% headwind in Q1 Rapid Assay revenue growth

    Mitigation: Internal platform shift to a higher-value instrument platform (Catalyst) which benefits other revenue streams.

    What to watch in Q2 FY25

    4

    IDEXX inVue Dx placement pace

    next quarter
    Current900 cumulative by end of April
    TargetContinued acceleration towards 4,500+ FY25 target

    Why it matters

    InVue Dx is a key new product launch expected to drive future consumables revenue and overall growth. Its placement pace indicates market adoption and execution.

    We look forward to sharing additional insights on utilization trends in the future. Looking ahead, we are in an excellent position for manufacturing, inventory and commercial capacity to deliver our 4,500-plus placement goal in 2025.

    Q&A highlights

    6

    Can you discuss the trends in total clinical visits, particularly the split between wellness and non-wellness, and your outlook for the rest of the year given the 2.6% decline in Q1?

    Management noted consistent trends with some quarter-to-quarter variation. Wellness visits saw some snapback due to the vector-borne disease screening season. The overall market overhang from macro factors continues to moderate wellness visits, but clinical visit moderation has stabilized. Practices are focused on re-engaging customers, and the quality of visits (diagnostic frequency and utilization) remains strong. The new Cancer Dx test is also seen as a potential tailwind for wellness screening.

    “We still think that the overall market overhang from a macro standpoint is providing some moderation, some headwinds to wellness visits. But in general, I think there's some level of optimism. The clinical visit moderation that we've seen has stabilized.”

    asked by Michael Ryskin · answered by Jay Mazelsky

    3 min read6 chapters

    Detailed Narrative

    01

    IDEXX Cancer Dx Launch and Early Adoption

    IDEXX launched its new Cancer Dx diagnostic panel for early detection of canine lymphoma through its North American reference labs at the end of March. This first-of-its-kind blood test is designed for broad inclusion in wellness visits due to its performance and pricing. Within one month of launch, over 1,000 unique practices have ordered the test, indicating strong initial interest and awareness among veterinarians. The company plans to broaden its oncology menu to address the majority of canine cancer cases within three years, leveraging its established diagnostic footprint.

    02

    IDEXX inVue Dx Rollout and Momentum

    The rollout of IDEXX inVue Dx, a new cellular analyzer, continued with 302 instruments placed in Q1. Following a controlled launch phase, the company moved to broad availability in April, resulting in an acceleration of placements to over 900 by the end of April. Customer feedback highlights ease of use, confidence in results, and enhanced technician workflows. The company remains confident in achieving its goal of 4,500+ placements in 2025 and plans to introduce fine needle aspirate (FNA) capabilities for lumps and bumps later in 2025, expanding its oncology diagnostic offerings.

    03

    Commercial Performance and International Growth

    IDEXX's commercial organization delivered solid organic recurring revenue growth, particularly in international markets which saw days-adjusted double-digit CAG Diagnostics recurring revenue growth. The company sustained high levels of customer retention and expanded its customer base, supported by strong premium instrument placements, including over 1,100 new and competitive Catalysts. Investments in commercial expansion, such as in South Korea, are aligned with regional readiness and commercial momentum, contributing to double-digit instrument installed base growth internationally.

    04

    Software Ecosystem as a Growth Driver

    The software ecosystem, including practice information management systems (PIMS) like ezyVet and Neo, and client engagement tools like Vello, continues to be a significant growth driver. The company reported double-digit placement growth in its cloud-native PIMS, particularly with multi-location practices and corporate accounts. Vello, the cloud-native client engagement platform, increased users over 20% from Q4, enhancing pet owner communications, increasing visit frequency, and improving compliance with diagnostics and treatment plans.

    05

    Navigating the Tariff Environment

    IDEXX is actively managing the dynamic global trade environment and potential tariff impact🌐s. While 65% of consolidated revenues and a majority of its CAG industrial base are U.S.-based, and China represents less than 1% of revenues, the company is not immune to tariffs. Management has incorporated estimates for China's retaliatory tariffs into its outlook and is focused on maintaining continuous supply to customers and minimizing financial impacts through operational planning and balance sheet leverage. Supply chains are described as resilient, prioritizing product availability.

    06

    Pet Healthcare Market Resiliency and Trends

    Despite macroeconomic conditions and moderated clinical visit growth, the pet healthcare market demonstrates resiliency. The estimated pet population sustained at similar levels to the prior year in 2024, representing approximately a 3% CAGR since 2019, well above historical rates. This higher baseline, combined with longer pet lifespans and an aging pet population, provides strong tailwinds for diagnostic use. Diagnostics remain central to pet care, with rising pet owner expectations for quality care.

    AI-generated summary of the company’s earnings call. Not investment advice.